
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc is experiencing positive momentum, particularly in the ACTH gel market, with projected revenue growth driven by increased demand for its products, especially Cortrophin Gel and legacy brands. The company anticipates an improvement in adjusted operating margin, rising to 29.7% by 2028, alongside a robust forecast of generating over $630 million in operating cash flow from 2025 to 2028. Recent quarterly results demonstrated strong performance, with raises in full-year 2025 revenue estimates, reflecting both solid volume growth in new product launches and continued strength in their generics segment.
Bears say
ANI Pharmaceuticals has experienced significant revenue declines in its Brands segment during the second and third quarters of 2024 due to unfavorable market conditions affecting certain molecules, particularly Cortrophin, which faced recurrent pricing headwinds. Management is anticipating a steep decline of over 30% in 1Q 2025 revenues due to seasonal impacts and Medicare access issues, particularly influenced by non-profit foundations failing to secure adequate funding for co-pays. Despite achieving total revenues of $190.6 million in the previous quarter, 9% above expectations, ongoing challenges in market access and pricing erosion for key products raise considerable concerns regarding the sustainability of future earnings.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares